RA Outcomes Improved in KURAMA Cohort - Summary - MDSpire

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

  • By

  • Andrea Surnit

  • May 22, 2026

  • 4 min

Share

Objective:

To analyze the long-term outcomes of patients with rheumatoid arthritis (RA) in the KURAMA cohort over a 10-year period.

Key Findings:
  • Include detail about methotrexate use remaining above 60% throughout the study period.
Interpretation:

Remove unsupported conclusions regarding the sensitivity of the Disease Activity Score 28-C-reactive protein.

Limitations:
  • Explicitly mention the lack of generalizability due to the single-center nature of the study.
Conclusion:

Remove unsupported summary statements about the transition of therapeutic strategies.

Original Source(s)

RA Outcomes Improved in KURAMA Cohort

  • by Andrea Surnit

  • May 22, 2026

Related Content

JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Sex Differences Seen in Immune Cells

Single-cell analysis identified sex-biased immune-cell composition, gene expression, and genetic regulation in unstimulated blood immune cells